CSHS WWW HOME | MS EXCHANGE LOG ON | PULSE ARCHIVES
Medical Staff Pulse is
a Publication of the Chief of Staff
Pharmacy Focus

Boxed warning added to Plavix®

The U.S. Food and Drug Administration has added a boxed warning to Plavix® (clopidogrel), alerting patients and healthcare professionals Plavix can be less effective in people who cannot metabolize the drug to convert it to its active form.

People who have reduced functioning of their CYP2C19 liver enzyme cannot convert Plavix to its active form. These "poor metabolizers" may not receive the full benefit of Plavix treatment and may remain at risk for heart attack, stroke and cardiovascular death. It is estimated that 2 percent to 14 percent of the U.S. population are poor metabolizers.

The FDA recommends that healthcare professionals consider alternative dosing of Plavix for these patients, or consider using other anti-platelet medications. Tests are available to assess CYP2C19 genotype to determine if a patient is a poor metabolizer.